Genefitletics

Clinical Research Program

Identify metabolic abnormalities in pathogenesis of diseases preceding breakdown in energetic process of mitochondria

The disease & gene based framework,driven by gene-protein-drug pipeline fails to identify early signs of cellular dysfunction for degenerative diseases & cancer

Access Research Our Program
8
Internal validation studies completed
35,000+
Scientific papers integrated into our models
7
Systemic diseases β€” early detection models
10M+
Molecular data points collected per sample

Genefitletics combines biophysics & exponential technologies to drive actionable insights & regenerative therapeutics for early disease diagnostics & restore cell collective intelligence.

The Problem

A critical gap in early diagnostics.

Modern healthcare, biomedical research & clinical practice are primarily focussed on disease based framework to address major diseases.This framework drives decision making based on knowledge & data around what goes wrong in diseases & what specific interventions could be effective in treating them. However, insights from diagnosis of diseases provide little inputs to identify the specific mechanisms causing their onset & actionables that could prevent them.

This practice has failed to differentiate between β€œhealth” & β€˜absence of disease’ & pinpoints a huge gap in clinical studies and commercialised applications of diagnostic solutions.

Genefitletics is focussed on engineering & reprogramming mitochondria & cellular communication network to drive to the future of early disease diagnostics.

πŸ”¬
Standard diagnostic tests cannot identify early stage abnormalities
Conventional tests detect disease after manifestation. Early cellular dysfunctions go undetected until damage is already done.
🧬
DNA testing is incomplete
DNA does not change during life and cannot reflect current health symptoms or the molecular mechanisms driving biological age.
πŸ“Š
Wearables lack molecular depth
Smart wearables cannot detect persistent cellular stressors or breakdown in biological communication at the molecular level.
⚑
No link between biology and intervention
Existing platforms lack the mathematical bridge between cellular pathway data and personalised regenerative therapeutics.
Our Research Program

What our clinical program targets.

Our program leverages existing cellular datasets to identify and measure early signals across the full spectrum of life-threatening diseases.

01
Molecular & Cellular Signatures
Identifying molecular and cellular signatures underlying metabolic disease and cancer β€” mapping how specific pathways break down before clinical symptoms appear.
02
Early Molecular Diagnostics
Building molecular diagnostics tests to predict and early-detect diseases and cancer β€” translating raw molecular data into actionable clinical signals.
03
Biological Age Mechanisms
Identifying molecular and cellular pathways that accelerate or decelerate biological age relative to chronological age β€” beyond telomere or DNA methylation testing.
04
Bioelectric Communication
Measuring breakdown in the cell’s electrical communication network β€” the earliest detectable signal preceding degenerative disease and cancer onset.
05
Microbiome–Mitochondria Crosstalk
Studying the bidirectional communication between gut/oral microbiome and mitochondrial function, and its role in systemic disease progression.
06
Precision Therapeutics Mapping
Mathematically combining 40,000+ nutrition substrates with molecular pathway data to construct interventions that reverse cellular stressors at their source.
Methodology

How we conduct our research.

A rigorous, data-driven process from cellular data collection to clinical validation.

1
Cellular Data Collection
10 million+ cellular data points sequenced from gut & oral microbiome gene expression per sample.
2
Pathway Scoring
Data translated into 100+ biological pathway scores and full-body insights using proprietary ML algorithms.
3
Longitudinal Tracking
200,000+ longitudinal metadata points per sample collected over time to track efficacy and revise interventions.
4
Clinical Validation
Outcomes validated against clinically validated questionnaires and real-world health improvements across 8 internal studies.
Featured Study

Biological Age & Longevity Study.

Study Overview

Identifying the molecular mechanisms that regulate biological age.

The current practice of assessing biological age is restricted to blood telomere testing, DNA methylation, or a few blood biomarkers. However these techniques do not provide a comprehensive view of an individual’s biochemistry at molecular & cellular level, and cannot identify the molecular mechanisms that regulate biological age.

This study aims to identify molecular and cellular pathways that make an individual age faster or slower relative to their chronological age β€” and provide nutritional therapeutics to reinstate cellular homeostasis and promote longevity.

Research Access Fee
β‚Ή18,000
Non-commercial use for projects benefiting human health may be eligible for waived access. Contact us to discuss.
Request Access
What the study measures
Molecular and cellular pathways influencing biological vs. chronological age β€” including mitochondrial function, microbiome activity, and cellular energetics markers.
Why current methods fall short
Telomere & DNA methylation testing provides no insight into current biochemistry. Our approach measures gene expression β€” which changes β€” not static DNA.
Therapeutic outcome
Personalised nutrition therapeutics in the form of food, food extracts, biotics, amino acids, herbs & adaptogens to reinstate cellular homeostasis and slow biological ageing.
Who this is for
Researchers, clinicians, longevity practitioners, and institutions seeking molecular-level insights into biological age and personalised anti-ageing interventions.
Access format
Full research methodology + molecular pathway data + personalised therapeutics recommendations. Fill the form below to get access.
Featured Study

Oral Cancer Early Detection Study.

Study Overview

Detecting oral cancer at stage 0–1 using the oral microbiome.

Oral cancer accounts for over 300,000 new cases globally each year. In India, it is the most common cancer in men, accounting for 1/3rd of the global incidences, yet the vast majority of cases are diagnosed at late stage and treated with a therapeutic approach having limited efficacy, resulting in survival rate below 20% and recurrence rate soaring to 40%.

The treatment approach focuses on eliminating cancer cells, or addressing mutations while there’s no concentrated effort being put to reprogram the mitochondria of the affected cells, so that they can rejoin the cell collective to drive large scale morphogenetic goals.

Standard diagnostics depend on physical examination and biopsy, missing the critical molecular window at stage 0–1 where intervention is most effective. Our study uses oral microbiome gene expression, sequencing 10M+ data points per sample- to identify the precise microbial and cellular pathway signatures that precede oral cancer onset.

10M+
Molecular data points per sample
Stage 0–1
Detection target β€” pre-clinical window
300,000
Cellular pathways mapped
Non-invasive
Saliva-based sample collection
Research Access Fee
Rs. 45000
Non-commercial use for projects benefiting human health may be eligible for waived access. Contact us to discuss.
Request Access
What the study measures
Oral microbiome gene expression across 10M+ molecular data points per sample – mapping microbial imbalances, cellular energetic stress, cytokine signalling, and bioelectric communication breakdown that precede oral cancer onset at stage 0–1.
Why current diagnostics miss early stage
Conventional oral cancer screening relies on visual examination and invasive biopsy β€” both of which only detect cancer after it has physically manifested. There are currently no molecular tools available to identify pre-clinical oral cancer signatures in routine clinical settings.
The 3 stages our model tracks
1
Cellular Recalibrations
2
Functional Dysregulation β€” microbiome–mitochondria breakdown
3
Bioelectric Network Collapse β€” cancer cell detachment from cell collective
Our model flags risk at Stage 1 β€” years before clinical symptoms appear.
Sample collection method
Non-invasive saliva-based sample collection. No biopsy, no blood draw. The saliva microbiome contains all the molecular information needed β€” including oral microbial pathways, mitochondrial function scores, and cellular pathway dysregulation markers.
Therapeutic outcomes
Personalised regenerative therapeutics β€” oral hygiene protocols, antimicrobial food extracts, biotics, peptides, bioregulators, and signalling molecules to reinstate ion channels β€” mathematically mapped to the patient’s dysregulated oral microbial pathways to reinstate oral cellular homeostasis and reduce cancer progression risk.
Who this study is for
Oral oncologists, dental clinicians, maxillofacial surgeons, cancer screening programmes, and research institutions seeking molecular-level early detection tools for oral cancer and pre-malignant oral conditions.
Access format
Access to detailed research + oral microbiome & mitochondrial functions analysis + personalised therapeutic protocol tied to current treatment practices. Submit a request below – our research team will review and respond within 2–3 business days.
Validated Outcomes

What our research has demonstrated.

Over 6 years, our solutions have shown measurable clinical improvements across multiple conditions.

Predicted Glycemic Response
Insulin prediction model for 300+ foods mapped with personalised oral & gut microbiome functions has clincally demonstrated 78% improvement in hyperglycemia.
Cardiovascular Disease
Therapeutic interventions demonstrated 75% improvement in molecular pathways & disease phenotype over a 3 year period.
Chronic Kidney Disease
Therapeutic interventions demonstrated 64% improvement in molecular pathways & disease phenotype over a 3 year period.
Gum Disease
Therapeutic interventions demonstrated 70% improvement in molecular pathways & disease phenotype over a 3 year period.
IBD
Therapeutic interventions demonstrated 80% improvement in molecular pathways & disease phenotype over a 3 year period.
Oral Cavities
Therapeutic interventions demonstrated 84% improvement in molecular pathways & disease phenotype over a 3 year period.
Get Access

Access our clinical research.

Those interested can get access to our research by filling in the form. Whether you are a clinician, researcher, or institution β€” we welcome collaborators committed to advancing early disease diagnostics.

βœ“
Full molecular pathway research report
βœ“
Personalised therapeutics recommendations
βœ“
Biological age assessment & insights
βœ“
Access to internal validation study data
βœ“
Non-commercial humanitarian access available

Request Research Access

✕
Genefitletics

FREE
VIEW